𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

✍ Scribed by Brufsky, Adam (author);Harker, W. Graydon (author);Beck, J. Thaddeus (author);Carroll, Robert (author);Tan-Chiu, Elizabeth (author);Seidler, Christopher (author);Hohneker, John (author);Lacerna, Leo (author);Petrone, Stephanie (author);Perez, Edith A. (author)

Book ID
127345121
Publisher
American Society of Clinical Oncology
Year
2007
Tongue
English
Weight
176 KB
Volume
25
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effective inhibition of aromatase inhibi
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results
✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the